A new publication concerning anamorelin appeared on August 14, 2026. The study is titled "Predictors of anamorelin discontinuation in patients with cancer-associated cachexia undergoing chemotherapy: A retrospective observational study." It was published in the International Journal of Clinical Pharmacology and Therapeutics.
The publication is described as a retrospective observational study. It focuses on patients with cancer-associated cachexia who were undergoing chemotherapy and had been treated with anamorelin. The listed title indicates the research examines factors associated with discontinuation of anamorelin in this patient population.
No specific findings, outcomes, or conclusions from the study have been provided in this notice. Anamorelin remains classified as an unapproved compound under research status. This brief reports only that the publication exists and identifies its title, journal, and date of appearance.
Readers interested in the details of the study, including any predictors identified or discontinuation rates reported, should consult the original publication directly through the journal or the linked source. For general background on anamorelin, including its research status and prior findings, see the compound overview.